CD4 and colitis: Another compound that targets S1P1/3/5 receptors, etrasimod, attenuated disease activity in the CD4+CD45RB+T-cell adoptive transfer colitis mouse model [178] and demonstrated therapeutic efficacy in a phase 2 clinical trial of patients with UC [179].